Inflectra® | Safety Profile & Efficacy

Ulcerative Colitis

In Adults

Inflectra® is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies2.

In Paediatrics

Inflectra® is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies2.

 

Click on the boxes below to read more data relating to Inflectra®:

Planetra: Safety and Efficacy in RA
GECSE KB, et al. 2017
PROSIT-BIO: Safety and Efficacy in UC and CD

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

PP-IFA-GBR-0321. December 2018

Planetas: Safety and Efficacy in AS
Study 3.4
Extrapolation of data for all licence indications